Cholesterol efflux pathways, inflammation, and atherosclerosis

References

• Annema W, Dikkers A, de Boer JF, van Greevenbroek MMJ, van der Kallen CJH, Schalkwijk CG, Stehouwer CDA, Dullaart RPF, Tietge UJF. 2016. Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study. Sci Rep. 6(1):27367.
   PubMedGoogle Scholar
• Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene I. 2002. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 106(1):24–30.
   PubMed Web of Science ®Google Scholar
• Bochem AE, van der Valk FM, Tolani S, Stroes ES, Westerterp M, Tall AR. 2015. Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by statins. Arterioscler Thromb Vasc Biol. 35(7):1663–1669.
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, Weil MT, Su M, Sen P, Ruhwedel T, Mitkovski M, Trendelenburg G, Lutjohann D, et al. 2018. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 359(6376):684–688.
   PubMed Web of Science ®Google Scholar
• Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. 1977. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 55(5):767–772.
   PubMed Web of Science ®Google Scholar
• Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. 2003. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell. 12(4):805–816.
   PubMed Web of Science ®Google Scholar
• Cedo L, Metso J, Santos D, Garcia-Leon A, Plana N, Sabate-Soler S, Rotllan N, Rivas-Urbina A, Mendez-Lara KA, Tondo M, et al. 2020. LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis: insight from mouse models. Circ Res. 127(6):778–792.
   PubMed Web of Science ®Google Scholar
• Cochain C, Saliba AE, Zernecke A. 2018. Letter by Cochain et al. regarding article, “transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models.” Circ Res. 123(11):e48–e49.
   PubMed Web of Science ®Google Scholar
• Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, Wolf D, Saliba AE, Zernecke A. 2018. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 122(12):1661–1674.
   PubMed Web of Science ®Google Scholar
• Coller BS. 2005. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? ATVB. 25(4):658–670.
   Google Scholar
• De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, et al. 2014. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 15(2):152–160.
   PubMed Web of Science ®Google Scholar
• Depuydt MAC, Prange KHM, Slenders L, Ord T, Elbersen D, Boltjes A, de Jager SCA, Asselbergs FW, de Borst GJ, Aavik E, et al. 2020. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ Res. 127(11):1437–1455.
   PubMed Web of Science ®Google Scholar
• Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Therond P, Chapman MJ, Kontush A, Wright SD. 2016. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. Circ Res. 119(6):751–763.
   PubMed Web of Science ®Google Scholar
• Dragoljevic D, Kraakman MJ, Nagareddy PR, Ngo D, Shihata W, Kammoun HL, Whillas A, Lee MKS, Al-Sharea A, Pernes G, et al. 2018. Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis. Eur Heart J. 39(23):2158–2167.
   PubMed Web of Science ®Google Scholar
• Dusuel A, Deckert V, Pais DEBJP, Van Dongen K, Choubley H, Charron E, Le Guern N, Labbe J, Mandard S, Grober J, et al. 2021. Human CETP lacks lipopolysaccharide transfer activity, but worsens inflammation and sepsis outcomes in mice. J Lipid Res. 62:100011.
   Web of Science ®Google Scholar
• Fotakis P, Kothari V, Bornfeldt KE, Tall AR. 2020. Response by Fotakis et al. to letter regarding article, “anti-inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques”. Arterioscl Thromb Vasc Biol. 40(2):e33–e34.
   PubMed Web of Science ®Google Scholar
• Fotakis P, Kothari V, Thomas DG, Westerterp M, Molusky MM, Altin E, Abramowicz S, Wang N, He Y, Heinecke JW, et al. 2019. Anti-inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques. ATVB. 39(12):e253–e272.
   Google Scholar
• Garg PK, Jorgensen NW, McClelland RL, Allison M, Stein JH, Yvan-Chavret L, Tall AR, Shea S. 2020. Cholesterol mass efflux capacity and risk of peripheral artery disease: the multi-ethnic study of atherosclerosis. Atherosclerosis. 297:81–86.
   PubMed Web of Science ®Google Scholar
• Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK. 2007. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell. 25(1):57–70.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, et al. 2021. Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Am Heart J. 231:121–127.
   PubMed Web of Science ®Google Scholar
• Gillard BK, Rosales C, Xu B, Gotto AM Jr, Pownall HJ. 2018. Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. J Clin Lipidol. 12(4):849–856.
   PubMed Web of Science ®Google Scholar
• Gille AW, S D, Tortorici M, Duffy D, Liss C, Yee MK, Deckelbaum LI, D’Andrea DM, Gibson CM. 2018. CSL112 restores cholesterol efflux in patients immediately after acute myocardial infarction. Circulation. 136:A16500.
   Google Scholar
• Glomset JA. 1968. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res. 9(2):155–167.
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 62(5):707–714.
   PubMed Web of Science ®Google Scholar
• Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, et al. 2017. Effects of anacetrapib in patients with atherosclerotic vascular disease. New Engl J Med. 377(13):1217–1227.
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Sulem P, Thorgeirsson G, Gretarsdottir S, Thorleifsson G, Jensson BO, Arnadottir GA, Olafsson I, Eyjolfsson GI, Sigurdardottir O, et al. 2018. Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. Eur Heart J. 39(23):2172–2178.
   PubMed Web of Science ®Google Scholar
• Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y. 1997. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 17(6):1053–1059.
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. New Engl J Med. 323(18):1234–1238.
   PubMed Web of Science ®Google Scholar
• Ito A, Hong C, Rong X, Zhu X, Tarling EJ, Hedde PN, Gratton E, Parks J, Tontonoz P. 2015. LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. eLife. 4:e08009.
   PubMed Web of Science ®Google Scholar
• Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR, van der Westhuyzen DR, de Beer FC. 2009. HDL remodeling during the acute phase response. ATVB. 29(2):261–267.
   Google Scholar
• Josefs T, Wouters K, Tietge UJF, Annema W, Dullaart RPF, Vaisar T, Arts ICW, van der Kallen CJH, Stehouwer CDA, Schalkwijk CG, et al. 2020. High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: the CODAM study. J Clin Lipidol. 14(1):122–132 e124.
   PubMed Web of Science ®Google Scholar
• Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 9(2):213–219.
   PubMed Web of Science ®Google Scholar
• Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M. 2014. Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol. 34(2):279–284.
   PubMed Web of Science ®Google Scholar
• Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. 2005. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1(2):121–131.
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 364(2):127–135.
   PubMed Web of Science ®Google Scholar
• Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S. 2017. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation. 135(25):2494–2504.
   PubMed Web of Science ®Google Scholar
• Khera AV, Rader DJ. 2013. Cholesterol efflux capacity: full steam ahead or a bump in the road? Arteriosclerosis, Thromb Vasc Biol. 33(7):1449–1451.
   PubMed Web of Science ®Google Scholar
• Kim K, Choi JH. 2018. Response by Kim and Choi to letter regarding article, “transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models.” Circ Res. 123(11):e50.
   PubMed Web of Science ®Google Scholar
• Kim K, Shim D, Lee JS, Zaitsev K, Williams JW, Kim KW, Jang MY, Seok Jang H, Yun TJ, Lee SH, et al. 2018. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res. 123(10):1127–1142.
   PubMed Web of Science ®Google Scholar
• Labzin LI, Schmidt SV, Masters SL, Beyer M, Krebs W, Klee K, Stahl R, Lutjohann D, Schultze JL, Latz E, et al. 2015. ATF3 Is a key regulator of macrophage IFN responses. J Immunol. 195(9):4446–4455.
   PubMed Web of Science ®Google Scholar
• Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, et al. 2013. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 33(7):1696–1705.
   PubMed Web of Science ®Google Scholar
• Madsen CM, Varbo A, Tybjaerg-Hansen A, Frikke-Schmidt R, Nordestgaard BG. 2018. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J. 39(14):1181–1190.
   PubMed Web of Science ®Google Scholar
• Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, Bittman R, Tall AR, Chen SH, Thomas MJ, et al. 2013. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Investig. 123(4):1571–1579.
   PubMed Web of Science ®Google Scholar
• Masucci-Magoulas L, Moulin P, Jiang XC, Richardson H, Walsh A, Breslow JL, Tall A. 1995. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J Clin Investig. 95(4):1587–1594.
   PubMed Web of Science ®Google Scholar
• Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. 2006. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Investig. 116(5):1435–1442.
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, Eugster A, Troullinaki M, Palladini A, Kourtzelis I, et al. 2018. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell. 172(1–2):147–161.
   PubMed Web of Science ®Google Scholar
• Monette JS, Hutchins PM, Ronsein GE, Wimberger J, Irwin AD, Tang C, Sara JD, Shao B, Vaisar T, Lerman A, et al. 2016. Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced hdl particle concentration. Circ Res. 119(1):83–90.
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Investig. 121(10):4138–4149.
   PubMed Web of Science ®Google Scholar
• Out R, Hoekstra M, Habets K, Meurs I, de Waard V, Hildebrand RB, Wang Y, Chimini G, Kuiper J, Van Berkel TJ, et al. 2008. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. ATVB. 28(2):258–264.
   Google Scholar
• Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. 2007. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 370(9602):1829–1839.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. 2017. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med. 377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, Libby P. 2020. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 41(23):2153–2163.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. 2019. Reverse cholesterol transport and atherosclerosis. Arterioscler Thromb Vasc Biol. 39(1):2–4.
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, et al. 2014. HDL cholesterol efflux capacity and incident cardiovascular events. New Engl J Med. 371(25):2383–2393.
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Westerterp M, Von Eckardstein A, Remaley AT, Rye KA. 2021. HDL in the 21st century: a multifunctional roadmap for future HDL research. Circulation. In press.
   Web of Science ®Google Scholar
• Rosales C, Gillard BK, Xu B, Gotto AM Jr, Pownall HJ. 2019. Revisiting reverse cholesterol transport in the context of high-density lipoprotein free cholesterol bioavailability. Methodist Debakey Cardiovasc J. 15(1):47–54.
   PubMedGoogle Scholar
• Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, et al. 2015. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 3(7):507–513.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Santos RD, Asztalos BF. 2010. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol. 21(4):289–297.
   PubMed Web of Science ®Google Scholar
• Shea S, Stein JH, Jorgensen NW, McClelland RL, Tascau L, Shrager S, Heinecke JW, Yvan-Charvet L, Tall AR. 2019. Cholesterol mass efflux capacity, incident cardiovascular disease, and progression of carotid plaque. ATVB. 39(1):89–96.
   Google Scholar
• Singh K, Chandra A, Sperry T, Joshi PH, Khera A, Virani SS, Ballantyne CM, Otvos JD, Dullaart RPF, Gruppen EG, et al. 2020. Associations between high-density lipoprotein particles and ischemic events by vascular domain, sex, and ethnicity: a pooled cohort analysis. Circulation. 142(7):657–669.
   PubMed Web of Science ®Google Scholar
• Smoak KA, Aloor JJ, Madenspacher J, Merrick BA, Collins JB, Zhu X, Cavigiolio G, Oda MN, Parks JS, Fessler MB. 2010. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab. 11(6):493–502.
   PubMed Web of Science ®Google Scholar
• Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, Reichart D, Fox JN, Shaked I, Heudobler D, et al. 2012. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 151(1):138–152.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Pritchard DK, Becker L, Hoofnagle AN, Tanimura N, Bammler TK, Beyer RP, Bumgarner R, Vaisar T, de Beer MC, et al. 2010. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation. 122(19):1919–1927.
   PubMed Web of Science ®Google Scholar
• Tall AR, Yvan-Charvet L. 2015. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 15(2):104–116.
   PubMed Web of Science ®Google Scholar
• Tall AR, Rader DJ. 2018. Trials and tribulations of CETP inhibitors. Circ Res. 122(1):106–112.
   PubMed Web of Science ®Google Scholar
• Tall AR, Westerterp M. 2019. Inflammasomes, neutrophil extracellular traps, and cholesterol. J Lipid Res. 60(4):721–727.
   PubMed Web of Science ®Google Scholar
• Thacker SG, Zarzour A, Chen Y, Alcicek MS, Freeman LA, Sviridov DO, Demosky SJ Jr, Remaley AT. 2016. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology. 149(3):306–319.
   PubMed Web of Science ®Google Scholar
• Thomas DG, Doran AC, Fotakis P, Westerterp M, Antonson P, Jiang H, Jiang X-C, Gustafsson J-A, Tabas IA, Tall AR. 2018. LXR suppresses inflammatory chromatin and neutrophil migration through a cis-repressive activity. Cell Rep. 25(13):3774–3785.
   PubMed Web of Science ®Google Scholar
• Thomas DG, Wei Y, Tall AR. 2021. Lipid and metabolic syndrome traits in coronary artery disease: a mendelian randomization study. J Lipid Res. 62(100044):1–13.
   Google Scholar
• Trigatti BL, Hegele RA. 2016. Rare genetic variants and high-density lipoprotein: marching to a different drum. Arterioscler Thromb Vasc Biol. 36(6):e53–55.
   PubMed Web of Science ®Google Scholar
• Trinder M, Walley KR, Boyd JH, Brunham LR. 2020. Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease. Arterioscler Thromb Vasc Biol. 40(1):267–278.
   PubMed Web of Science ®Google Scholar
• Trinder M, Wang Y, Madsen CM, Ponomarev T, Bohunek L, Daisely BA, Julia Kong H, Blauw LL, Nordestgaard BG, Tybjaerg-Hansen A, et al. 2021. Inhibition of cholesteryl ester transfer protein preserves high-density lipoprotein cholesterol and improves survival in sepsis. Circulation. 143(9):921–934.
   PubMed Web of Science ®Google Scholar
• van der Velde AE, Vrins CL, van den Oever K, Kunne C, Oude Elferink RP, Kuipers F, Groen AK. 2007. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 133(3):967–975.
   PubMed Web of Science ®Google Scholar
• van der Vorst EPC, Biessen EAL, Donners M. 2020. Letter by van der Vorst et al. regarding article, “anti-Inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques”. Arterioscler Thromb Vasc Biol. 40(2):e31–e32.
   PubMed Web of Science ®Google Scholar
• van der Vorst EPC, Theodorou K, Wu Y, Hoeksema MA, Goossens P, Bursill CA, Aliyev T, Huitema LFA, Tas SW, Wolfs IMJ, et al. 2017. High-density lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol depletion and PKC-NF-kappaB/STAT1-IRF1 signaling. Cell Metab. 25(1):197–207.
   PubMed Web of Science ®Google Scholar
• Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 380(9841):572–580.
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Chen W, Matsuura F, Tall AR. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. PNAS. 101(26):9774–9779.
   PubMed Web of Science ®Google Scholar
• Wang N, Silver DL, Costet P, Tall AR. 2000. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem. 275(42):33053–33058.
   PubMed Web of Science ®Google Scholar
• Wang M, Subramanian M, Abramowicz S, Murphy AJ, Gonen A, Witztum J, Welch C, Tabas I, Westerterp M, Tall AR. 2014. Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler Thromb Vasc Biol. 34(5):976–984.
   PubMed Web of Science ®Google Scholar
• Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR. 2014. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ Res. 114(1):157–170.
   PubMed Web of Science ®Google Scholar
• Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Wang W, Abramowicz S, la Bastide-van Gemert S, Wang N, et al. 2018. Cholesterol efflux pathways suppress inflammasome activation, NETosis and atherogenesis. Circulation. 138(9):898–912.
   PubMed Web of Science ®Google Scholar
• Westerterp M, Gautier EL, Ganda A, Molusky MM, Wang W, Fotakis P, Wang N, Randolph GJ, D’Agati VD, Yvan-Charvet L, et al. 2017. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 25(6):1294–1304 e1296.
   PubMed Web of Science ®Google Scholar
• Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, Gorman DJ, Nagareddy PR, Zhu X, Abramowicz S, et al. 2013. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res. 112(11):1456–1465.
   PubMed Web of Science ®Google Scholar
• Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, et al. 2006. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 281(38):27816–27826.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR. 2010. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 30(7):1430–1438.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, et al. 2010. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 328(5986):1689–1693.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. 2007. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Investig. 117(12):3900–3908.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Swirski FK. 2018. Is defective cholesterol efflux an integral inflammatory component in myelopoiesis-driven cardiovascular diseases? Eur Heart J. 39(23):2168–2171.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, Ishibashi M, Li R, Wang N, Tall AR. 2008. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 118(18):1837–1847.
   PubMed Web of Science ®Google Scholar
• Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, DerOhannessian S, Kontush A, Surendran P, Saleheen D, et al. 2016. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 351(6278):1166–1171.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, Willingham MC, Hiltbold EM, Mishra N, et al. 2008. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem. 283(34):22930–22941.
   PubMed Web of Science ®Google Scholar